menu
    • menu
    [{"orgOrder":0,"company":"Biolojic Design","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Antibody-based therapy","moa":"","graph1":"Endocrinology","graph2":"Discovery Platform","graph3":"Biolojic Design","amount2":0.12,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Endocrinology","amount2New":0.12,"dosageForm":"","sponsorNew":"Biolojic Design \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Biolojic Design \/ Eli Lilly"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Aulos","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biolojic Design","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biolojic Design \/ Biolojic Design","highestDevelopmentStatusID":"7","companyTruncated":"Biolojic Design \/ Biolojic Design"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Aulos","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Aldesleukin","moa":"IL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biolojic Design","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Biolojic Design \/ Biolojic Design","highestDevelopmentStatusID":"7","companyTruncated":"Biolojic Design \/ Biolojic Design"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"BD9","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Biolojic Design","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Biolojic Design \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"4","companyTruncated":"Biolojic Design \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Biolojic Design","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Biolojic Design \/ Nektar Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Biolojic Design \/ Nektar Therapeutics"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biolojic Design","amount2":0.38,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.38,"dosageForm":"","sponsorNew":"Biolojic Design \/ Merck KGaA","highestDevelopmentStatusID":"3","companyTruncated":"Biolojic Design \/ Merck KGaA"}]

    Find Clinical Drug Pipeline Developments & Deals by Biolojic Design

    Menu

    Biolojic Design

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biolojic Design

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Biolojic Design

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Merck Group

                            Deal Size : $376.3 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Biolojic, Merck KGaA Multi-Target Drug Discovery Collaboration

                            Details : The collaboration will leverage Biolojic Design’s AI-driven discovery platform to design therapeutic antibodies for the treatment of cancer and immunological disorders.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 03, 2024

                            Lead Product(s) : Antibody-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Merck Group

                            Deal Size : $376.3 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biolojic Design

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Biolojic Design

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Nektar Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biolojic Design Announces Nektar to Develop AI-Designed Antibody for Autoimmune Diseases

                            Details : Through the license agreement, Nektar will utilize the Biolojic Design program TNFR2 receptor agonist, currently undergoing early-stage clinical trials for treating autoimmune diseases.

                            Brand Name : Undiclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 24, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Nektar Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biolojic Design

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Biolojic Design

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BD9

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody fo...

                            Details : Under the agreement, Teva will receive exclusive rights to develop, manufacture and commercialize a potential novel antibody-based therapy, BD9, a dual specific antibody that can block both TSLP and IL-13, for the treatment of Atopic Dermatitis and Asthm...

                            Brand Name : BD9

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 14, 2023

                            Lead Product(s) : BD9

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biolojic Design

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Biolojic Design

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AU-007,Aldesleukin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Aulos

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aulos Bioscience Initiates Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 for the Treatment of Solid Tumo...

                            Details : AU-007 is a human monoclonal antibody computationally designed by Biolojic Design, with a highly differentiated approach to harnessing the power of interleukin-2 (IL-2) to eradicate solid tumors.

                            Brand Name : AU-007

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 05, 2022

                            Lead Product(s) : AU-007,Aldesleukin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Aulos

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Biolojic Design

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Biolojic Design

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AU-007,Aldesleukin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Aulos

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First-Ever Computationally Designed Antibody, Created by Biolojic Design, Entering Human Clinical Trial In Can...

                            Details : The trial will evaluate AU-007, a highly differentiated monoclonal antibody that was computationally designed by Biolojic and harnesses the power of the body's own interleukin-2 (IL-2) to eradicate solid cancer tumors.

                            Brand Name : AU-007

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 05, 2022

                            Lead Product(s) : AU-007,Aldesleukin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Aulos

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Biolojic Design

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Biolojic Design

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-based therapy

                            Therapeutic Area : Endocrinology

                            Study Phase : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $121.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabe...

                            Details : The research collaboration and license agreement that will leverage Biolojic's AI-based multibody platform to discover and develop a potential novel antibody-based therapy for the treatment of diabetes.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 08, 2021

                            Lead Product(s) : Antibody-based therapy

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $121.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth